title: Influence of CYP2D6 genotype on the disposition of the enantiomers of venlafaxine and its major metabolites in postmortem femoral blood.
abstract: Venlafaxine (VEN) is an antidepressant drug mainly metabolized by the cytochrome P450 (CYP) enzyme CYP2D6 to the active metabolite O-desmethylvenlafaxine (ODV). VEN is also metabolized to N-desmetylvenlafaxine (NDV) via CYP3A4. ODV and NDV are further metabolized to N,O-didesmethylvenlafaxine (DDV). VEN is a racemic mixture of the S- and R-enantiomers and these have in vitro displayed different degrees of serotonin and noradrenaline reuptake inhibition. The aim of the study was to investigate if an enantioselective analysis of VEN and its metabolites, in combination with genotyping for CYP2D6, could assist in the interpretation of forensic toxicological results in cases with different causes of deaths. Concentrations of the enantiomers of VEN and metabolites were determined in femoral blood obtained from 56 autopsy cases with different causes of death. The drug analysis was done by liquid chromatography tandem mass spectrometry (LC/MS/MS) and the CYP2D6 genotyping by PCR and pyrosequencing. The mean (median) enantiomeric S/R ratios of VEN, ODV, NDV and DDV were 0.99 (0.91), 2.17 (0.93), 0.92 (0.86) and 1.08 (1.03), respectively. However, a substantial variation in the relationship between the S- and R-enantiomers of VEN and metabolites was evident (S/R ratios ranging from 0.23 to 17.6). In six cases, a low S/R VEN ratio (mean 0.5) was associated with a high S/R ODV ratio (mean 11.9). Genotyping showed that these individuals carried two inactive CYP2D6 genes indicating a poor metabolizer phenotype. From these data we conclude that enantioselective analysis of VEN and ODV can predict if a person is a poor metabolizer genotype/phenotype for CYP2D6. Knowledge of the relationship between the S- and R-enantiomers of this antidepressant drug and its active metabolite is also important since the enantiomers display different pharmacodynamic profiles.
authors.affiliation: Division of Drug Research, Clinical Pharmacology, Department of Medical and Health Sciences, Linköping University, Linköping, Sweden.
authors.forename: Maria
authors.initials: M
authors.lastname: Kingbäck
authors.forename: Louise
authors.initials: L
authors.lastname: Karlsson
authors.forename: Anna-Lena
authors.initials: AL
authors.lastname: Zackrisson
authors.forename: Björn
authors.initials: B
authors.lastname: Carlsson
authors.forename: Martin
authors.initials: M
authors.lastname: Josefsson
authors.forename: Finn
authors.initials: F
authors.lastname: Bengtsson
authors.forename: Johan
authors.initials: J
authors.lastname: Ahlner
authors.forename: Fredrik C
authors.initials: FC
authors.lastname: Kugelberg
mesh_terms: D018687:Antidepressive Agents, Second-Generation / Q000097:blood*; D002853:Chromatography, Liquid; D003511:Cyclohexanols / Q000097:blood*; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics*; D000069468:Desvenlafaxine Succinate; D053593:Forensic Toxicology; D005838:Genotype; D006801:Humans; D013237:Stereoisomerism; D053719:Tandem Mass Spectrometry; D000069470:Venlafaxine Hydrochloride
chemical_list: D018687:Antidepressive Agents, Second-Generation; D003511:Cyclohexanols; D000069470:Venlafaxine Hydrochloride; C434333:N,O-didesmethylvenlafaxine; D019389:Cytochrome P-450 CYP2D6; D000069468:Desvenlafaxine Succinate